Heterogeneity of immunostaining for tumour markers in non-small cell lung carcinoma

被引:4
|
作者
Macdonald, C [1 ]
Michael, A [1 ]
Colston, K [1 ]
Mansi, J [1 ]
机构
[1] St George Hosp, Sch Med, Div Oncol Gastroenterol & Metab, London SW17 0RE, England
关键词
lung carcinoma; immunohistochemistry; Ki-67; p53; bcl-2; prognostic significance;
D O I
10.1016/j.ejca.2003.10.019
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Lung carcinoma is a leading cause of death. However, there are few indicators that can aid in prediction and prognosis. Many tumour markers are available, but their reliability is questionable. For example, Ki-67 expression has been associated with increased as well as decreased survival or with no clinical significance. The varying results have been attributed to the methodology, relative intensity of staining, variety of marking and statistical methods. To determine whether differential expression of markers within tumours may be a contributory factor to this lack of agreement, we used two marking methods to evaluate the level of expression of Ki-673 p53 and bcl-2, in addition to the apoptotic index, in serial sections of non-small cell carcinoma. All stains exhibited a degree of heterogeneity. This small study highlights the importance of standardisation of marking methods and interpretation of results if tumour markers are to be used as predictive or prognostic factors. (C) 2003 Elsevier Ltd. All rights reserved.
引用
收藏
页码:461 / 466
页数:6
相关论文
共 50 条
  • [41] KRAS Amplification in Non-Small Cell Lung Carcinoma
    Stiedl, A. C.
    Wagner, P. L.
    Wilbertz, T.
    Altorki, N. K.
    Perner, S. R.
    MODERN PATHOLOGY, 2010, 23 : 414A - 414A
  • [42] NON-SMALL CELL-CARCINOMA OF THE LUNG - INTRODUCTION
    GOLOMB, HM
    SEMINARS IN ONCOLOGY, 1983, 10 (01) : 1 - 2
  • [43] Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer
    Rice, Shawn J.
    Belani, Chandra P.
    PLOS ONE, 2021, 16 (12):
  • [44] Expression of Immune Cell Markers in Non-Small Cell Lung Cancer
    Wan, Haitao
    Zhang, Yuping
    Sui, Yingzhong
    Han, Shuhong
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2020, 127 : 142 - 142
  • [45] Predictive molecular markers in non-small cell lung cancer
    Rosell, R
    Tarón, M
    O'Brate, A
    CURRENT OPINION IN ONCOLOGY, 2001, 13 (02) : 101 - 109
  • [46] Prognostic molecular markers in non-small cell lung cancer
    Niklinski, J
    Niklinska, W
    Laudanski, J
    Chyczewska, E
    Chyczewski, L
    LUNG CANCER, 2001, 34 : S53 - S58
  • [47] Global proteomic profiling identifies etoposide chemoresistance markers in non-small cell lung carcinoma
    Paul, Debasish
    Chanukuppa, Venkatesh
    Reddy, Panga Jaipal
    Taunk, Khushman
    Adhav, Ragini
    Srivastava, Sanjeeva
    Santra, Manas Kumar
    Rapole, Srikanth
    JOURNAL OF PROTEOMICS, 2016, 138 : 95 - 105
  • [48] MARKERS OF PROLIFERATION ACTIVITY IN NON-SMALL CELL LUNG CANCER
    Vasutova, I.
    Skrickova, J.
    Stankova, Y.
    Babickova, L.
    Tomiskova, M.
    Kadlec, B.
    Pavlovsky, Z.
    Kren, L.
    Chroust, K.
    LUNG CANCER, 2009, 64 : S30 - S31
  • [49] MOLECULAR MARKERS IN NON-SMALL CELL LUNG CANCER (NSCLC)
    Heigener, D.
    ANTICANCER RESEARCH, 2011, 31 (05) : 1979 - 1979
  • [50] Prognostic Immune Markers in Non-Small Cell Lung Cancer
    Suzuki, Kei
    Kachala, Stefan S.
    Kadota, Kyuichi
    Shen, Ronglai
    Mo, Qianxing
    Beer, David G.
    Rusch, Valerie W.
    Travis, William D.
    Adusumilli, Prasad S.
    CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5247 - 5256